Suppr超能文献

基于氨基酸配方奶粉缓解牛奶过敏症状的疗效:一项系统评价。

The efficacy of amino acid-based formulas in relieving the symptoms of cow's milk allergy: a systematic review.

作者信息

Hill D J, Murch S H, Rafferty K, Wallis P, Green C J

机构信息

Department of Allergy, Royal Children's Hospital, Melbourne, Australia.

出版信息

Clin Exp Allergy. 2007 Jun;37(6):808-22. doi: 10.1111/j.1365-2222.2007.02724.x.

Abstract

The aim of this systematic review was to evaluate the efficacy of amino acid-based formulas (AAF) in patients with cow's milk allergy (CMA). Studies were identified using electronic databases and bibliography searches. Subjects eligible for inclusion were patients of any age with CMA or symptoms suggestive of it. Comparisons of interest were AAF vs. extensively hydrolysed formula (eHF), AAF vs. soy-based formula (SF) and AAF vs. cow's milk or cow's milk-based formula. Outcomes of interest were gastrointestinal (GI), dermatological, respiratory and behavioural symptoms as well as growth. A total of 20 studies [three head-to-head randomized controlled trials (RCTs), three cross-over challenge RCTs, seven clinical trials (CTs) and seven case reports (CRs)] were included in the review. In infants with confirmed or suspected CMA, the use of an AAF was shown to be safe and efficacious. Findings from RCT comparisons of AAF with eHF showed that both formulas are equally efficacious at relieving the symptoms of CMA in confirmed or suspected cases. However, infants in specific subgroups (e.g. non-IgE mediated food-induced gastro-enterocolitis-proctitis syndromes with failure to thrive, severe atopic eczema, or with symptoms during exclusive breastfeeding) were more likely overall to benefit from AAF, as intolerance to eHF may occur. In such cases, symptoms persisting despite eHF feeding usually remit on AAF, and catch-up growth may be seen. Meta-analysis of the findings was not possible due to lack of homogenous reporting of outcomes in the original trials. This systematic review shows clinical benefit from use of AAF in both symptoms and growth in infants and children with CMA who fail to tolerate eHF. Further studies are required to determine the relative medical or economic value of initial treatment with AAF in infants at high risk of eHF intolerance.

摘要

本系统评价的目的是评估氨基酸配方奶粉(AAF)对牛奶蛋白过敏(CMA)患者的疗效。通过电子数据库和文献检索来确定研究。纳入的合格受试者为任何年龄的CMA患者或有相关症状提示的患者。感兴趣的比较包括AAF与深度水解配方奶粉(eHF)、AAF与大豆配方奶粉(SF)以及AAF与牛奶或牛奶蛋白配方奶粉。感兴趣的结局包括胃肠道(GI)、皮肤、呼吸和行为症状以及生长情况。本评价共纳入了20项研究[三项头对头随机对照试验(RCT)、三项交叉激发RCT、七项临床试验(CT)和七项病例报告(CR)]。在确诊或疑似CMA的婴儿中,使用AAF被证明是安全有效的。AAF与eHF的RCT比较结果显示,在确诊或疑似病例中,两种配方奶粉在缓解CMA症状方面同样有效。然而,特定亚组的婴儿(如非IgE介导的食物诱导性胃肠结肠炎 - 直肠炎综合征伴生长发育不良、重度特应性皮炎或纯母乳喂养期间出现症状者)总体上更可能从AAF中获益,因为可能会出现对eHF不耐受的情况。在这种情况下,尽管使用eHF喂养但症状持续的情况通常在使用AAF后缓解,并且可能会出现追赶生长。由于原始试验中结局报告缺乏同质性,因此无法进行结果的荟萃分析。本系统评价表明,对于不耐受eHF的CMA婴幼儿,使用AAF在症状和生长方面均有临床益处。需要进一步研究以确定在有eHF不耐受高风险的婴儿中初始使用AAF的相对医学或经济价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验